We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




PSA Assays Added to Tumor Marker Portfolio

By LabMedica International staff writers
Posted on 16 Dec 2008
A comprehensive tumor marker portfolio has added total prostate-specific antigen (PSA) assay and free PSA assays to its menu.

Prostate cancer is the second leading cause of cancer death in men. More...
Therefore, it is recommended that all men 50 or older be screened for prostate cancer by having an annual PSA test. If detected in its early stages, the 5-year survival rate for prostate cancer is nearly 100%.

Roche Diagnostics (Basel, Switzerland) has introduced the Elecsys total PSA and Elecsys free PSA assays to its immunoassay tumor marker menu for use on the Roche cobas 6000 analyzer series.

The advantages of the Roche Elecsys total and free PSA assays include better precision, an 18-minute turnaround time, and a convenient 20-μL-sample size for both assays. The tumor marker portfolio has a menu that already includes alpha fetal protein (AFP), carcinoembryonic antigen (CEA), cancer antigen (CA) 19-9 (mainly used for pancreatic cancer), CA 15-3 (for monitoring breast cancer) and CA 125 (for ovarian cancer). Currently these assays are also available for use on the Roche Elecsys 2010 system and the Modular Analytics E 170 module.

Roche Diagnostics offers a broad portfolio of diagnostics tools that test for congestive heart failure, human immunodeficiency virus (HIV), Hepatitis B and C, fertility testing, diabetes, and many other diseases. This wide array of testing products and services is supplied to physicians, patients, hospitals, and laboratories.

Related Links:
Roche Diagnostics


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Rapid Molecular Testing Device
FlashDetect Flash10
Sample Transportation System
Tempus1800 Necto
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more

Pathology

view channel
Image: The AI tool advances precision diagnostics by linking genetic mutations directly to disease types (Photo courtesy of Shutterstock)

AI Tool Simultaneously Identifies Genetic Mutations and Disease Type

Interpreting genetic test results remains a major challenge in modern medicine, particularly for rare and complex diseases. While existing tools can indicate whether a genetic mutation is harmful, they... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.